The ALS Association was started in 1985, and they still have not invested in any new cures for ALS. One of the latest failures was Biogen’s drug dexpramipexole, which halted research in early 2013. The drug was in research for more than 10 years at an estimated cost of between $75 million and $100 million, but was abandoned in last stage development due to poor results. Financials: We pulled up their 2013 tax returns to take a closer look at how their funds are spent. Here are the salaries for the leadership of the group: - Jane H. Gilbert – President and CEO – $339,475.00 - Daniel M. Reznikov – Chief Financial Officer – $201,260.00 - Steve Gibson – Chief Public Policy Officer – $182,862.00 - Kimberly Maginnis - Chief of Care Services Officer – $160,646.00 - Lance Slaughter - Chief Chapter Relations and Development Officer – $152,692.00 - Michelle Keegan – Chief Development Officer – $178,744.00 - John Applegate – Association Finance Officer – $118.726.00 - David Moses – Director of Planned Giving – $112,509.00 - Carrie Munk – Chief Communications and Marketing Officer – $142,875.00 - Patrick Wildman – Director of Public Policy – $112,358.00 - Kathi Kromer – Director of State Advocacy – $110,661.00 Total administration costs, as seen in the pie chart above, were just under $2 million. “Other salaries and wages” (Part IX line 7) were $3.6 million, with another half million dollars in “pension plans” and “employee benefits.” Expenses for non-employee labor were about $4 million, and “travel expenses” exceeded $1.3 million.
Posted on: Tue, 26 Aug 2014 11:48:45 +0000